In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 41% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION IN PAH-CTD PATIENTS TREATED WITH UPTRAVI® VS PLACEBO1*
Time to first disease progression event in patients with PAH-CTD
![Percent of patients without an event in the PAH-CTD subgroup analysis desktop curve](/assets/images/3.4_t1_44-percent-km_chart.png)
![Percent of patients without an event in the PAH-CTD subgroup analysis mobile curve](/assets/images/3.4_t1_44-percent-km_chart--mobile.png)
![41% risk reduction HR 0.59 (95% CI: 0.41, 0.85)](/assets/images/3.4_t1_risk-reduction_chevron.png)
Baseline patient characteristics
- 29% (n=334) of all patients in GRIPHON had PAH-CTD
- PAH-CTD subtypes: PAH-SSc (51%, n=170), PAH-SLE (24.5%, n=82), PAH-MCTD/CTD-Other (24.5%, n=82)†
- 46% of patients in the PAH-CTD subgroup were FC II and 53% were FC III
- 28% were receiving PDE-5i monotherapy, 23% were not receiving PAH background therapy, 20% were receiving ERA monotherapy, and 29% were receiving an ERA + PDE-5i at baseline
- Time from diagnosis: UPTRAVI® (1.6 years), placebo (1.7 years)
- Average age: UPTRAVI® (52 years), placebo (53 years)
Summary of primary endpoint events in patients with PAH-CTD
![Events in patients with PAH-SSc desktop table](/assets/images/3.4_t1_primary-endpoint_table.png)
![Events in patients with PAH-SSc mobile table](/assets/images/3.4_t1_primary-endpoint_table--mobile.png)
Adverse reactions in the PAH-CTD subpopulation occurring more frequently with UPTRAVI® compared with placebo by ≥3%
![Adverse reactions in the PAH-SSc subgroup notably different from the overall population mobile table](/assets/images/3.4_t1_adverse-reactions_table--mobile.png)
PAH-CTD was a prespecified subgroup for evaluation of the primary endpoint; however, the more detailed analyses described here are post hoc. Sample size should be considered and results should be interpreted with caution.
In an exploratory post hoc subgroup analysis, UPTRAVI® was associated with a: 44% RELATIVE RISK REDUCTION OF DISEASE PROGRESSION IN PAH-SSc PATIENTS TREATED WITH UPTRAVI® VS PLACEBO1*
Time to first disease progression event in patients with PAH-SSc
![Percent of patients without an event in the PAH-SSc subgroup analysis desktop curve](/assets/images/3.4_t2_44-percent-km_chart.png)
![Percent of patients without an event in the PAH-SSc subgroup analysis mobile curve](/assets/images/3.4_t2_44-percent-km_chart--mobile.png)
![44% risk reduction HR 0.56 (95% CI: 0.34, 0.91)](/assets/images/3.4_t2_risk-reduction_chevron.png)
Baseline patient characteristics
Of the 334 patients with PAH-CTD in GRIPHON, 51% (n=170) had PAH-SSc.
- 34% FC II, 65% FC III, and 2% FC I or FC IV
- 78% of patients were receiving PAH background therapy (36% receiving an ERA + PDE-5i, 23% receiving a PDE-5i only, and 18% receiving an ERA only)
- Time from diagnosis: UPTRAVI® (1.5 years), placebo (1.6 years)
- Average age: UPTRAVI® (59 years), placebo (61 years)
Summary of primary endpoint events in patients with PAH-SSc
![Events in patients with PAH-SSc desktop table](/assets/images/3.4_t2_primary-endpoint_table.png)
![Events in patients with PAH-SSc mobile table](/assets/images/3.4_t2_primary-endpoint_table--mobile.png)
Adverse reactions in the PAH-SSc subpopulation occurring more frequently with UPTRAVI® compared with placebo by ≥3%
![Adverse reactions in the PAH-SSc subgroup notably different from the overall population mobile table](/assets/images/3.4_t2_adverse-reactions_table--mobile.png)
This subgroup analysis was post hoc and exploratory in nature. Sample size should be considered and results should be interpreted with caution.